Connect with us
  • Elysium


Your NR headlines: Tuesday 6th February

Welcome to your daily round-up of everything happening in the world of neurorehabilitation.



Daily News Round Up: Tuesday, 26 March

Welcome to your daily round-up of everything happening in the world of neurorehabilitation.

Research news

Healthy lifestyles can stave off dementia

New research from brain autopsies has suggested that a healthy lifestyle could prevent dementia, as people build up ‘cognitive reserve’ over the course of their lives. According to the findings, this enables brains to  maintain good function even though neurological signs of dementia may develop.

Could mitochondria be key to treating Alzheimer’s? 

Research has revealed that energy production can be disrupted before the onset of Alzheimer’s disease which is tied to mitochondria disfunction. Now, researchers have deciphered the part of the Krebs cycle, a series of reactions in the mitochondria, that is disrupted in people with Alzheimer’s disease, providing hope for future drug development.

Blood test pinpoints cause of brain injury in newborns

A study from Imperial College London found that patterns of gene expression detectable in blood can reveal the cause of injury in babies with a type of brain injury caused by hypoxia. The test can also inform doctors on whether or not the newborn is likely to respond to cooling treatment.

New MRI procedure visualises myelin sheaths

A team of researchers have developed a new MRI procedure that maps the condition of myelin sheaths. the procedure could have big implications for Multiple Sclerosis patients, a condition which causes the immune system to destroy a person’s myelin sheaths, as well as allowing improved visualisation of other solid tissue types such as connective tissue, tendons and ligaments.

Reducing chronic pain in Parkinson’s

What causes chronic pain in Parkinson’s Disease is so far unknown, however, a team of researchers from the University of South Australia are now hoping to find out in a bid to help improve quality of life for patients.

Improving understanding of GI tract’s response to TBIs

New findings have deepened our understanding of the response of the GI tract to TBIs. In a new paper, published in Nature, researchers have demonstrated how TBIs induce an “early, transient increase in intestinal permeability and a bloom of A. muciniphila that corresponds temporally with increased medial colon goblet cell density and increased colon hypoxia in the absence of altered GI tract morphology.” The researchers suggest the increase in A. muciniphila following a TBI may be a beneficial compensatory alteration in the gut microbiome in order to limit histological damage to the GI tract, encouraging further investigation into interventions that prolong or promote the growth of the bacteria as novel therapeutics after TBI.

Understanding how we speak could provide hope speech disorders

A new study has shed light on how neurons in the human brain work together to allow people to think about what words they want to say and then produce them aloud through speech. The findings, which map how speech sounds are represented in the brain, could lead to improvements in the treatment of speech and language disorders.

Company and financial neuro-rehab news

ReWalk Robotics rebrands to Lifeward

ReWalk, which services include the ReWalk Personal Exoskeleton, ReStore Exo-Suit and MyoCycle FES systems for mobility rehabilitation, has rebranded to Lifeward. CEO Larry Jasinski discusses the company’s recent M&A of AlterG and the product offering that has now been added to Lifeward’s portfolio of offerings.

Phase2 trial for concussion treatment

Oragenics has announced it is now advancing to its Phase II clinical trial for lead drug candidate ONP-002. The drug is aimed at treating concussion and is delivered as a self-propelled powdered nanoparticle into the nasal cavity.

NEO provides hope for spine injury patients

A new brain-computer interface implant – NEO – could provide hope for spinal cord injury patients as the implant does not need a battery to work. Instead, the implant is powered remotely through an inductive high-frequency antenna and transmits epidural ECoG wirelessly to a receiver attached outside the scalp. So far, the implant has been successfully implanted into two patients, with the next phase aiming to develop a new protocol of BCI-facilitated active rehabilitation.

Net revenue drop of 6.4% for AbbVie in 2023

AbbVie, the pharmaceutical firm with a significant presence in the neuro-rehab field, has announced its annual results, with net revenues decreasing to $54.32bn for the year. This marks a 6.4% decline from the previous year’s $58.05bn, and its diluted earnings per share also fell sharply by 59% to $2.72, compared to $6.63 in 2022. Adjusted diluted EPS saw a 19.3% decrease from $13.77 to $11.11.

Injectable electrode may advance neuromodulation pain treatment

Neuronoff, Inc. has developed a minimally invasive injectable electrode which offers a simple treatment alternative for chronic pain sufferers while avoiding the need for medications or invasive surgeries. The company has now successfully conducted the first human implant of the Injectrode.

Synchron acquires equity stake in Acquandas

Synchron has announced the acquisition of an equity stake in Acquandas, which will see Synchron CEO and founder Tom Oxley join the Acquandas governance council, and Synchron CTO Riki Banerjee will join as observer.